维普中文期刊产品整合服务
6篇 您的检索式:作者名="Chris Estes"
    题名 作者 年代 出处 被引量
1Global epidemiology and genotype distribution of the hepatitis C virus infection显示文摘Erin Gower Chris Estes Sarah Blach Kathryn Razavi-Shearer Homie Razavi 2014Journal of Hepatology2014,,1:10
2Chronic hepatitis C virus (HCV) disease burden and cost in the United States显示文摘Homie Razavi Antoine C. ElKhoury Elamin Elbasha Chris Estes Ken Pasini Thierry Poynard Ritesh Kumar 2013Hepatology2013,,6:2
3Homie Razavi Global epidemiology and genotype distribution of the hepatitis C virus infection显示文摘Erin Gower Chris Estes Sarah Blach Kathryn Razavi- Shearer 2014Journal of Hepatology2014,61,:1
4The Globalization of Capital: The Welfare State, and Old Age Policy显示文摘Cawoll Estes Simon Biggs and Chris Phillipson 2002lnternationd Journal oJ' Health Services2002,32,2:1
5Enhanced antiviral treatment efficacy and uptake in preventing the rising burden of hepatitis C ‐related liver disease and costs in A ustralia显示文摘William Sievert Homie Razavi Chris Estes Alexander J Thompson Amany Zekry Stuart K Roberts Gregory J Dore 2014J Gastroenterol Hepatol2014,,:1
6Hepatitis C virus infection in Argentina: Burden of chronic disease显示文摘AIM: To estimate the progression of the hepatitis C virus(HCV) epidemic and measure the burden of HCVrelated morbidity and mortality. METHODS: Age- and gender-defined cohorts were used to follow the viremic population in Argentina and estimate HCV incidence, prevalence, hepatic complications, and mortality. The relative impact of two scenarios on HCV-related outcomes was assessed:(1) increased sustained virologic response(SVR); and(2) increased SVR and treatment.RESULTS: Under scenario 1, SVR raised to 85%-95% in 2016. Compared to the base case scenario, there was a 0.3% reduction in prevalent cases and liverrelated deaths by 2030. Given low treatment rates, cases of hepatocellular carcinoma and decompensated cirrhosis decreased < 1%, in contrast to the base case in 2030. Under scenario 2, the same increases in SVR were modeled, with gradual increases in the annual diagnosed and treated populations. This scenario decreased prevalent infections 45%, liver-related deaths 55%, liver cancer cases 60%, and decompensated cirrhosis 55%, as compared to the base case by 2030. CONCLUSION: In Argentina, cases of end stage liver disease and liver-related deaths due to HCV are still growing, while its prevalence is decreasing. Increasing in SVR rates is not enough, and increasing in the number of patients diagnosed and candidates for treatment is needed to reduce the HCV disease burden. Based on this scenario, strategies to increase diagnosis and treatment uptake must be developed to reduce HCV burden in Argentina.Ezequiel Ridruejo Fernando Bessone Jorge R Daruich Chris Estes Adrián C Gadano Homie Razavi Federico G Villamil Marcelo O Silva 2016World Journal of Hepatology2016,8,15:0
返回顶部 每页显示:
共1页 首页 上一页 第1页 下一页 末页 /1 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费